Company:  ALLENA PHARMACEUTICALS, I ... (ALNA)
Form Type:  PRE 14A
Filing Date:  4/12/2021 
CIK:  0001624658 
Address:  ONE NEWTON EXECUTIVE PARK
SUITE 202
 
City, State, Zip:  NEWTON, Massachusetts 02462 
Telephone:  617-467-4577 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$1.10  
Change: 
-0.04 (-3.51%)  
Trade Time: 
May 14  
Market Cap: 
$63.46M
Trade ALNA now with 

© 2021  
Description of Business
We are a late-stage, clinical biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. We are focused on metabolic disorders that result in excess accumulation of certain metabolites that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease, or ESRD. We believe our proprietary know-how in enzyme technology allows for the design, development, formulation, and scalable manufacturing of non-absorbed and stable enzymes delivered orally and in sufficient doses for activity in the gastrointestinal tract. This approach enables us to develop enzyme therapies that degrade metabolites within the GI tract, which reduces potentially toxic metabolite levels in the blood and urine, and in turn, diminishes the disease burden including on the kidney over time.
Register and access this filing in:     
  FORM PRE 14A
    NOTICE OF 2021 ANNUAL MEETING OF STOCKHOLDERS
    PROXY STATEMENT FOR THE 2021 ANNUAL MEETING OF STOCKHOLDERS
    Will My Shares Be Voted if I Do Not Return My Proxy Card or ...
    PROPOSAL 1
      NAME AND TITLE
      NAME AND TITLE
      NAME AND TITLE
    AUDIT COMMITTEE REPORT
    Compensation Committee Interlocks and Insider Participation
    PROPOSAL 2
    PROPOSAL 3
    EXECUTIVE COMPENSATION
      OPTIONS AGGREGATE
    DIRECTOR COMPENSATION
    SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
      BENEFICIAL OWNERS
    STOCKHOLDER PROPOSALS AND NOMINATIONS
    OTHER MATTERS